25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

EZ1 (Enzon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Enzon together

I guess you are interested in ENZON PHARM (EZ1.SG). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Enzon’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Enzon’s Price Targets

I'm going to help you getting a better view of ENZON PHARM (EZ1.SG). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ENZON PHARM (EZ1.SG)

I send you an email if I find something interesting about ENZON PHARM (EZ1.SG).

1. Quick Overview

1.1. Quick analysis of Enzon (30 sec.)










1.2. What can you expect buying and holding a share of Enzon? (30 sec.)

How much money do you get?

How much money do you get?
€0.02
When do you have the money?
1 year
How often do you get paid?
16.7%

What is your share worth?

Current worth
€0.04
Expected worth in 1 year
€0.03
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
€0.01
Return On Investment
14.0%

For what price can you sell your share?

Current Price per Share
€0.07
Expected price per share
€0.0555 - €0.098
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Enzon (5 min.)




Live pricePrice per Share (EOD)
€0.07
Intrinsic Value Per Share
€0.32 - €0.38
Total Value Per Share
€0.35 - €0.42

2.2. Growth of Enzon (5 min.)




Is Enzon growing?

Current yearPrevious yearGrowGrow %
How rich?$3m$2.9m$71.2k2.4%

How much money is Enzon making?

Current yearPrevious yearGrowGrow %
Making money$194.5k$343.2k-$148.7k-76.5%
Net Profit Margin265.4%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Enzon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Enzon?

Welcome investor! Enzon's management wants to use your money to grow the business. In return you get a share of Enzon.

First you should know what it really means to hold a share of Enzon. And how you can make/lose money.

Speculation

The Price per Share of Enzon is €0.0665. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enzon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enzon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.04. Based on the TTM, the Book Value Change Per Share is €0.00 per quarter. Based on the YOY, the Book Value Change Per Share is €0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enzon.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps0.00-1.5%0.003.9%0.007.0%0.003.3%0.000.2%0.00-0.7%
Usd Book Value Change Per Share0.005.0%0.00-2.5%0.000.5%-0.05-74.9%0.00-3.1%0.002.5%
Usd Dividend Per Share0.000.0%0.006.5%0.006.5%0.004.3%0.002.6%0.018.9%
Usd Total Gains Per Share0.005.0%0.003.9%0.007.0%-0.05-70.6%0.00-0.5%0.0111.4%
Usd Price Per Share0.14-0.11-0.15-0.18-0.23-0.23-
Price to Earnings Ratio-35.37--3.87-11.79--31.30-5.90--4.30-
Price-to-Total Gains Ratio41.41--5.84--15.47--147.33--109.37--122.19-
Price to Book Ratio3.39-2.68-3.86-2.73-2.49-2.38-
Price-to-Total Gains Ratio41.41--5.84--15.47--147.33--109.37--122.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0748125
Number of shares13366
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (13366 shares)35.03-4.48
Gains per Year (13366 shares)140.12-17.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1230-9013092-110-28
2459-179270184-220-46
3689-269410276-329-64
4919-358550367-439-82
51148-448690459-549-100
61378-537830551-659-118
71607-627970643-768-136
81837-7161110735-878-154
92067-8061250827-988-172
102296-8951390919-1098-190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%8.04.00.066.7%9.011.00.045.0%9.015.00.037.5%9.015.00.037.5%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.016.00.020.0%5.019.00.020.8%5.019.00.020.8%
Dividend per Share1.00.03.025.0%2.00.010.016.7%2.00.018.010.0%4.00.020.016.7%4.00.020.016.7%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%6.014.00.030.0%8.016.00.033.3%8.016.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ENZON PHARM (EZ1.SG) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.003-0.001+151%0.000+904%-0.044+1602%-0.002+162%0.002+96%
Book Value Per Share--0.0360.036-1%0.035+2%0.168-79%0.205-82%0.189-81%
Current Ratio--28.10084.570-67%93.028-70%90.877-69%85.345-67%73.664-62%
Debt To Asset Ratio--0.9360.936+0%0.9370%0.704+33%0.521+80%0.461+103%
Debt To Equity Ratio--14.68114.619+0%15.138-3%11.002+33%7.196+104%6.041+143%
Dividend Per Share---0.004-100%0.004-100%0.003-100%0.002-100%0.005-100%
Enterprise Value---30200531.334-32014388.412+6%-29279555.077-3%-17733015.801-41%-6084134.633-80%-3127635.079-90%
Eps---0.0010.002-137%0.004-121%0.002-144%0.000-878%0.000-54%
Free Cash Flow Per Share--0.0030.003-19%0.004-31%0.002+53%0.001+410%0.001+410%
Free Cash Flow To Equity Per Share--0.0030.000+117%0.000+2913%-0.001+129%0.025-89%0.025-89%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.381----------
Intrinsic Value_10Y_min--0.319----------
Intrinsic Value_1Y_max--0.012----------
Intrinsic Value_1Y_min--0.011----------
Intrinsic Value_3Y_max--0.055----------
Intrinsic Value_3Y_min--0.052----------
Intrinsic Value_5Y_max--0.123----------
Intrinsic Value_5Y_min--0.112----------
Market Cap4935270.900-83%9054181.5667133878.713+27%9842711.723-8%11719722.724-23%15366133.492-41%15014850.959-40%
Net Profit Margin---2.654-100%-0%1.952-100%-9.9310%-15.5770%
Operating Margin----0%-0%-0%-10.6390%-16.1620%
Operating Ratio---3.375-100%-0%1.885-100%12.521-100%17.813-100%
Pb Ratio1.846-83%3.3862.680+26%3.858-12%2.726+24%2.492+36%2.378+42%
Pe Ratio-19.278+45%-35.367-3.869-89%11.788-400%-31.302-11%5.897-700%-4.304-88%
Price Per Share0.067-83%0.1220.096+27%0.133-8%0.158-23%0.207-41%0.202-40%
Price To Free Cash Flow Ratio6.142-83%11.2687.757+45%11.155+1%14.584-23%151.196-93%125.996-91%
Price To Total Gains Ratio22.570-83%41.406-5.843+114%-15.466+137%-147.330+456%-109.369+364%-122.186+395%
Quick Ratio----0%-0%-0%-0%-0%
Return On Assets---0.0020.004-137%0.007-121%0.003-144%-0.006+309%-0.009+510%
Return On Equity---0.0240.064-137%0.113-121%0.066-136%0.028-185%0.018-232%
Total Gains Per Share--0.0030.002+26%0.004-28%-0.042+1516%0.000+110%0.007-56%
Usd Book Value--3008037.6003025787.822-1%2954536.931+2%14005758.403-79%17080263.501-82%15745613.484-81%
Usd Book Value Change Per Share--0.003-0.002+151%0.000+904%-0.050+1602%-0.002+162%0.002+96%
Usd Book Value Per Share--0.0410.041-1%0.040+2%0.189-79%0.230-82%0.212-81%
Usd Dividend Per Share---0.004-100%0.004-100%0.003-100%0.002-100%0.006-100%
Usd Enterprise Value---33975597.751-36016186.963+6%-32939499.462-3%-19949642.776-41%-6844651.462-80%-3518589.464-90%
Usd Eps---0.0010.003-137%0.005-121%0.002-144%0.000-878%0.000-54%
Usd Free Cash Flow--226002.825280503.506-19%326254.078-31%147335.175+53%44350.554+410%36958.795+511%
Usd Free Cash Flow Per Share--0.0030.004-19%0.004-31%0.002+53%0.001+410%0.001+410%
Usd Free Cash Flow To Equity Per Share--0.003-0.001+117%0.000+2913%-0.001+129%0.028-89%0.028-89%
Usd Market Cap5552179.763-83%10185954.2628025613.553+27%11073050.688-8%13184688.064-23%17286900.179-41%16891707.328-40%
Usd Price Per Share0.075-83%0.1370.108+27%0.149-8%0.178-23%0.233-41%0.228-40%
Usd Profit---72000.900194502.431-137%343254.291-121%163752.047-144%9250.116-878%-33083.747-54%
Usd Revenue---6500.081-100%-0%4333.388-100%40250.503-100%46417.247-100%
Usd Total Gains Per Share--0.0030.003+26%0.005-28%-0.047+1516%0.000+110%0.008-56%
 EOD+3 -5MRQTTM+14 -21YOY+13 -193Y+14 -215Y+13 -2110Y+11 -23

3.3 Fundamental Score

Let's check the fundamental score of ENZON PHARM (EZ1.SG) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-19.278
Price to Book Ratio (EOD)Between0-11.846
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than128.100
Debt to Asset Ratio (MRQ)Less than10.936
Debt to Equity Ratio (MRQ)Less than114.681
Return on Equity (MRQ)Greater than0.15-0.024
Return on Assets (MRQ)Greater than0.05-0.002
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of ENZON PHARM (EZ1.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.731
Ma 20Greater thanMa 500.066
Ma 50Greater thanMa 1000.073
Ma 100Greater thanMa 2000.094
OpenGreater thanClose0.065
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About ENZON PHARM (EZ1.SG)

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Fundamental data was last updated by Penke on 2025-04-25 06:32:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Enzon earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Enzon to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ €0.00 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM265.4%-265.4%
TTM265.4%YOY-+265.4%
TTM265.4%5Y-993.1%+1,258.5%
5Y-993.1%10Y-1,557.7%+564.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--88.9%+88.9%
TTM265.4%-182.1%+447.5%
YOY--195.7%+195.7%
3Y195.2%-244.6%+439.8%
5Y-993.1%-350.0%-643.1%
10Y-1,557.7%-491.0%-1,066.7%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Enzon is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Enzon to theΒ Biotechnology industry mean.
  • -0.2% Return on Assets means thatΒ Enzon generatedΒ €0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ENZON PHARM (EZ1.SG):

  • The MRQ is -0.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.4%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.2%TTM0.4%-0.6%
TTM0.4%YOY0.7%-0.3%
TTM0.4%5Y-0.6%+1.0%
5Y-0.6%10Y-0.9%+0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.2%-11.3%+11.1%
TTM0.4%-11.5%+11.9%
YOY0.7%-11.5%+12.2%
3Y0.3%-11.9%+12.2%
5Y-0.6%-12.5%+11.9%
10Y-0.9%-14.1%+13.2%
4.3.1.3. Return on Equity

Shows how efficient Enzon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Enzon to theΒ Biotechnology industry mean.
  • -2.4% Return on Equity means Enzon generated €-0.02Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ENZON PHARM (EZ1.SG):

  • The MRQ is -2.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 6.4%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM6.4%-8.8%
TTM6.4%YOY11.3%-4.9%
TTM6.4%5Y2.8%+3.6%
5Y2.8%10Y1.8%+1.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.4%-14.5%+12.1%
TTM6.4%-15.1%+21.5%
YOY11.3%-15.0%+26.3%
3Y6.6%-17.5%+24.1%
5Y2.8%-18.0%+20.8%
10Y1.8%-19.9%+21.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ENZON PHARM (EZ1.SG).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Enzon is operatingΒ .

  • Measures how much profit Enzon makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Enzon to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-1,063.9%+1,063.9%
5Y-1,063.9%10Y-1,616.2%+552.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--177.6%+177.6%
TTM--289.9%+289.9%
YOY--208.5%+208.5%
3Y--248.9%+248.9%
5Y-1,063.9%-360.9%-703.0%
10Y-1,616.2%-475.6%-1,140.6%
4.3.2.2. Operating Ratio

Measures how efficient Enzon is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.375-3.375
TTM3.375YOY-+3.375
TTM3.3755Y12.521-9.146
5Y12.52110Y17.813-5.292
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.175-2.175
TTM3.3753.048+0.327
YOY-3.051-3.051
3Y1.8853.656-1.771
5Y12.5214.839+7.682
10Y17.8136.533+11.280
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ENZON PHARM (EZ1.SG).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Enzon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 28.10Β means the company has €28.10 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 28.100. The company is very able to pay all its short-term debts. +2
  • The TTM is 84.570. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ28.100TTM84.570-56.470
TTM84.570YOY93.028-8.458
TTM84.5705Y85.345-0.775
5Y85.34510Y73.664+11.681
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.1003.588+24.512
TTM84.5703.932+80.638
YOY93.0284.286+88.742
3Y90.8774.809+86.068
5Y85.3455.816+79.529
10Y73.6646.204+67.460
4.4.3.2. Quick Ratio

Measures if Enzon is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Enzon to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off €0.00 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.845-2.845
TTM-3.439-3.439
YOY-4.128-4.128
3Y-4.673-4.673
5Y-5.938-5.938
10Y-6.556-6.556
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ENZON PHARM (EZ1.SG).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of EnzonΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Enzon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.94Β means that Enzon assets areΒ financed with 93.6% credit (debt) and the remaining percentage (100% - 93.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 0.936. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.936. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.936TTM0.936+0.001
TTM0.936YOY0.937-0.001
TTM0.9365Y0.521+0.414
5Y0.52110Y0.461+0.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9360.342+0.594
TTM0.9360.342+0.594
YOY0.9370.330+0.607
3Y0.7040.329+0.375
5Y0.5210.359+0.162
10Y0.4610.382+0.079
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Enzon is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Enzon to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 1,468.1% means that company has €14.68 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ENZON PHARM (EZ1.SG):

  • The MRQ is 14.681. The company is unable to pay all its debts with equity. -1
  • The TTM is 14.619. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ14.681TTM14.619+0.062
TTM14.619YOY15.138-0.519
TTM14.6195Y7.196+7.424
5Y7.19610Y6.041+1.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.6810.410+14.271
TTM14.6190.427+14.192
YOY15.1380.408+14.730
3Y11.0020.428+10.574
5Y7.1960.447+6.749
10Y6.0410.494+5.547
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Enzon generates.

  • Above 15 is considered overpriced butΒ always compareΒ Enzon to theΒ Biotechnology industry mean.
  • A PE ratio of -35.37 means the investor is paying €-35.37Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ENZON PHARM (EZ1.SG):

  • The EOD is -19.278. Based on the earnings, the company is expensive. -2
  • The MRQ is -35.367. Based on the earnings, the company is expensive. -2
  • The TTM is -3.869. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.278MRQ-35.367+16.089
MRQ-35.367TTM-3.869-31.498
TTM-3.869YOY11.788-15.657
TTM-3.8695Y5.897-9.767
5Y5.89710Y-4.304+10.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.278-1.735-17.543
MRQ-35.367-2.410-32.957
TTM-3.869-3.010-0.859
YOY11.788-3.337+15.125
3Y-31.302-4.007-27.295
5Y5.897-6.317+12.214
10Y-4.304-6.805+2.501
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ENZON PHARM (EZ1.SG):

  • The EOD is 6.142. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 11.268. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 7.757. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD6.142MRQ11.268-5.126
MRQ11.268TTM7.757+3.511
TTM7.757YOY11.155-3.398
TTM7.7575Y151.196-143.439
5Y151.19610Y125.996+25.199
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.142-2.387+8.529
MRQ11.268-3.244+14.512
TTM7.757-3.963+11.720
YOY11.155-4.345+15.500
3Y14.584-5.424+20.008
5Y151.196-8.416+159.612
10Y125.996-9.392+135.388
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Enzon is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 3.39 means the investor is paying €3.39Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of ENZON PHARM (EZ1.SG):

  • The EOD is 1.846. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.386. Based on the equity, the company is fair priced.
  • The TTM is 2.680. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.846MRQ3.386-1.540
MRQ3.386TTM2.680+0.706
TTM2.680YOY3.858-1.178
TTM2.6805Y2.492+0.188
5Y2.49210Y2.378+0.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8461.723+0.123
MRQ3.3862.114+1.272
TTM2.6802.377+0.303
YOY3.8582.474+1.384
3Y2.7262.757-0.031
5Y2.4923.696-1.204
10Y2.3784.294-1.916
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Net Income  597-313284-39245-20226-290-64
Net Income from Continuing Operations  597-313284-39245-20226-290-64



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets47,169
Total Liabilities44,161
Total Stockholder Equity3,008
 As reported
Total Liabilities 44,161
Total Stockholder Equity+ 3,008
Total Assets = 47,169

Assets

Total Assets47,169
Total Current Assets47,152
Long-term Assets17
Total Current Assets
Cash And Cash Equivalents 46,859
Other Current Assets 293
Total Current Assets  (as reported)47,152
Total Current Assets  (calculated)47,152
+/-0
Long-term Assets
Long-term Assets  (as reported)17
Long-term Assets  (calculated)0
+/- 17

Liabilities & Shareholders' Equity

Total Current Liabilities1,678
Long-term Liabilities42,483
Total Stockholder Equity3,008
Total Current Liabilities
Accounts payable 331
Other Current Liabilities 5
Total Current Liabilities  (as reported)1,678
Total Current Liabilities  (calculated)336
+/- 1,342
Long-term Liabilities
Long-term Liabilities  (as reported)42,483
Long-term Liabilities  (calculated)0
+/- 42,483
Total Stockholder Equity
Total Stockholder Equity (as reported)3,008
Total Stockholder Equity (calculated)0
+/- 3,008
Other
Capital Stock742
Common Stock Shares Outstanding 74,215
Net Invested Capital 3,008
Net Working Capital 45,474



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
12,554
12,403
12,070
6,478
6,237
6,004
5,824
48,232
48,292
48,246
47,963
47,754
47,470
47,224
47,257
47,589
46,495
46,672
46,997
47,702
46,829
46,994
47,276
47,169
47,16947,27646,99446,82947,70246,99746,67246,49547,58947,25747,22447,47047,75447,96348,24648,29248,2325,8246,0046,2376,47812,07012,40312,554
   > Total Current Assets 
11,584
11,433
11,100
5,993
6,237
6,004
5,824
48,232
48,292
48,246
47,963
47,754
47,470
47,224
47,257
47,387
46,257
46,485
46,886
47,343
46,469
46,638
46,970
47,152
47,15246,97046,63846,46947,34346,88646,48546,25747,38747,25747,22447,47047,75447,96348,24648,29248,2325,8246,0046,2375,99311,10011,43311,584
       Cash And Cash Equivalents 
3,558
3,367
10,016
5,446
5,144
5,909
5,311
48,142
48,187
48,191
47,891
47,641
47,429
46,794
46,852
46,982
45,877
46,131
46,557
47,012
45,988
46,229
46,633
46,859
46,85946,63346,22945,98847,01246,55746,13145,87746,98246,85246,79447,42947,64147,89148,19148,18748,1425,3115,9095,1445,44610,0163,3673,558
       Other Current Assets 
56
96
114
62
123
95
56
59
40
55
72
85
41
430
405
405
380
354
329
331
481
409
337
293
2933374094813313293543804054054304185725540595695123621149656
   > Long-term Assets 
970
970
970
485
0
0
0
0
0
0
0
0
0
0
0
202
238
187
111
359
360
356
306
17
1730635636035911118723820200000000000485970970970
       Long-term Assets Other 
970
970
970
485
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000485970970970
> Total Liabilities 
585
455
5,753
423
424
427
654
40,872
41,427
434
377
403
410
377
425
44,182
43,422
43,947
44,482
44,197
43,535
43,955
44,514
44,161
44,16144,51443,95543,53544,19744,48243,94743,42244,18242537741040337743441,42740,8726544274244235,753455585
   > Total Current Liabilities 
585
455
5,753
423
424
427
654
412
461
434
377
403
410
377
425
1,699
408
402
406
1,714
521
410
438
1,678
1,6784384105211,7144064024081,6994253774104033774344614126544274244235,753455585
       Accounts payable 
490
348
346
324
322
314
306
302
329
331
331
331
331
331
331
331
331
331
337
331
331
331
331
331
331331331331331337331331331331331331331331331329302306314322324346348490
       Other Current Liabilities 
0
0
0
18
0
0
0
18
0
0
0
11
0
0
0
6
0
0
0
16
0
20
6
5
56200160006000110001800018000
   > Long-term Liabilities 
0
0
0
0
0
0
0
40,460
40,966
0
0
0
0
0
0
42,483
43,014
43,545
44,076
42,483
43,014
43,545
44,076
42,483
42,48344,07643,54543,01442,48344,07643,54543,01442,48300000040,96640,4600000000
> Total Stockholder Equity
11,969
11,948
6,317
6,055
5,813
5,577
5,170
7,360
6,865
47,812
47,586
47,351
47,060
46,847
46,832
3,407
3,073
2,725
2,515
3,505
3,294
3,039
2,762
3,008
3,0082,7623,0393,2943,5052,5152,7253,0733,40746,83246,84747,06047,35147,58647,8126,8657,3605,1705,5775,8136,0556,31711,94811,969
   Common Stock000000000000000000000000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue26
Cost of Revenue--
Gross Profit-26
 
Operating Income (+$)
Gross Profit-
Operating Expense-1,353
Operating Income-1,327-1,353
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,353
Selling And Marketing Expenses-
Operating Expense1,3531,353
 
Net Interest Income (+$)
Interest Income2,452
Interest Expense--
Other Finance Cost-0
Net Interest Income2,452
 
Pretax Income (+$)
Operating Income-1,327
Net Interest Income2,452
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,125-1,327
EBIT - interestExpense = 0
778
778
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-1,125
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax1,125
Tax Provision-347
Net Income From Continuing Ops778778
Net Income778
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--2,452
 

Technical Analysis of Enzon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enzon. The general trend of Enzon is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enzon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Enzon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ENZON PHARM (EZ1.SG).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.0865 < 0.092 < 0.098.

The bearish price targets are: 0.0615 > 0.0595 > 0.0555.

Know someone who trades $EZ1? Share this with them.πŸ‘‡

ENZON PHARM (EZ1.SG) Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ENZON PHARM (EZ1.SG). The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ENZON PHARM (EZ1.SG) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ENZON PHARM (EZ1.SG). The current macd is -0.002732.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Enzon price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Enzon. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Enzon price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ENZON PHARM (EZ1.SG) Daily Moving Average Convergence/Divergence (MACD) ChartENZON PHARM (EZ1.SG) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ENZON PHARM (EZ1.SG). The current adx is 26.23.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Enzon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
ENZON PHARM (EZ1.SG) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ENZON PHARM (EZ1.SG). The current sar is 0.09273035.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ENZON PHARM (EZ1.SG) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ENZON PHARM (EZ1.SG). The current rsi is 46.73. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
ENZON PHARM (EZ1.SG) Daily Relative Strength Index (RSI) ChartENZON PHARM (EZ1.SG) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ENZON PHARM (EZ1.SG). The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Enzon price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
ENZON PHARM (EZ1.SG) Daily Stochastic Oscillator ChartENZON PHARM (EZ1.SG) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ENZON PHARM (EZ1.SG). The current cci is -4.30107527.

ENZON PHARM (EZ1.SG) Daily Commodity Channel Index (CCI) ChartENZON PHARM (EZ1.SG) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ENZON PHARM (EZ1.SG). The current cmo is -0.48671039.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
ENZON PHARM (EZ1.SG) Daily Chande Momentum Oscillator (CMO) ChartENZON PHARM (EZ1.SG) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ENZON PHARM (EZ1.SG). The current willr is -83.13253012.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
ENZON PHARM (EZ1.SG) Daily Williams %R ChartENZON PHARM (EZ1.SG) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of ENZON PHARM (EZ1.SG).

ENZON PHARM (EZ1.SG) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ENZON PHARM (EZ1.SG). The current atr is 0.00525166.

ENZON PHARM (EZ1.SG) Daily Average True Range (ATR) ChartENZON PHARM (EZ1.SG) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ENZON PHARM (EZ1.SG). The current obv is 39,050.

ENZON PHARM (EZ1.SG) Daily On-Balance Volume (OBV) ChartENZON PHARM (EZ1.SG) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ENZON PHARM (EZ1.SG). The current mfi is 100.00.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
ENZON PHARM (EZ1.SG) Daily Money Flow Index (MFI) ChartENZON PHARM (EZ1.SG) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ENZON PHARM (EZ1.SG).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

ENZON PHARM (EZ1.SG) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ENZON PHARM (EZ1.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.731
Ma 20Greater thanMa 500.066
Ma 50Greater thanMa 1000.073
Ma 100Greater thanMa 2000.094
OpenGreater thanClose0.065
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Enzon with someone you think should read this too:
  • Are you bullish or bearish on Enzon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enzon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ENZON PHARM (EZ1.SG)

I send you an email if I find something interesting about ENZON PHARM (EZ1.SG).


Comments

How you think about this?

Leave a comment

Stay informed about ENZON PHARM (EZ1.SG).

Receive notifications about ENZON PHARM (EZ1.SG) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.